Assessing the burden of respiratory syncytial virus disease in Australia

Hannah C Moore and Christopher C Blyth
Med J Aust 2019; 210 (10): . || doi: 10.5694/mja2.50173
Published online: 3 June 2019

National reporting for all age groups is needed to accurately determine the full burden of disease

Respiratory syncytial virus (RSV) is a pathogen of global importance, responsible each year for more than 33 million infections, 3.2 million hospitalisations, and 59 600 in‐hospital deaths of children under 5 years of age.1 The full burden of disease is likely to be much higher, as 50% of deaths occur outside hospitals.2 The World Health Organization regards RSV vaccine development as a global priority,3 and RSV vaccines have been short‐listed for the Global Vaccine Alliance (Gavi) vaccine investment strategy; several vaccine candidates and monoclonal antibodies are being investigated, and it is anticipated that commercial vaccines will be available by 2025.4,5 Gaps in knowledge about the epidemiology of RSV — accurate burden of disease estimates, its long term effects, seasonal transmission dynamics, the cost of RSV‐related disease — need to be filled to guide vaccine policy and implementation.6

  • 1 Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, WA
  • 2 University of Western Australia, Perth, WA

Competing interests:

No relevant disclosures.

  • 1. Shi T, McAllister DA, O'Brien KL, et al.; RSV Global Epidemiology Network. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet 2017; 390: 946–958.
  • 2. Cohen C, Walaza S, Treurnicht FK, et al. In‐ and out‐of‐hospital mortality associated with seasonal and pandemic influenza and respiratory syncytial virus in South Africa, 2009–2013. Clin Infect Dis 2018; 66: 95–103.
  • 3. Vekemans J, Moorthy V, Giersing B, et al. Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics. Vaccine 2018; [Epub ahead of print].
  • 4. Gavi (The Vaccine Alliance). Vaccine investment strategy. (viewed Apr 2019).
  • 5. PATH. RSV vaccine and mAb snapshot. Apr 2019. (viewed Apr 2019).
  • 6. Kim L, Rha B, Abramson JS, et al. Identifying gaps in respiratory syncytial virus disease epidemiology in the United States prior to the introduction of vaccines. Clin Infect Dis 2017; 65: 1020–1025.
  • 7. Novavax. Novavax announces topline results from phase 3 PrepareTM trial of ResVax for prevention of RSV disease in infants via maternal immunization [media release]. 28 Feb 2019. (viewed Apr 2019).
  • 8. Saravanos GL, Sheel M, Homaira N, et al. Respiratory syncytial virus‐associated hospitalisations in Australia, 2006–2015. Med J Aust 2019; 210: 447–453.
  • 9. Lim FJ, Blyth CC, Fathima P, et al. Record linkage study of the pathogen‐specific burden of respiratory viruses in children. Influenza Other Respir Viruses 2017; 11: 502–510.
  • 10. Bhuiyan MU, Snelling TL, West R, et al. The contribution of viruses and bacteria to community‐acquired pneumonia in vaccinated children: a case–control study. Thorax 2019; 74: 261–269.
  • 11. Christenen D, Davis G, Draper G, et al. Evidence for the use of an algorithm in resolving inconsistent and missing Indigenous status in administrative data collections. Aust J Soc Issues 2014; 49: 423–443.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.